LumiraDx Presents LumiraDx Point of Care Instrument at IFCC EUROMEDLAB
By LabMedica International staff writers Posted on 11 Apr 2022 |
LumiraDx (London, UK) participated in the IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine (EUROMEDLAB) hosted by the German Society of Clinical Chemistry and Laboratory Medicine (DGKL), one of the oldest national societies devoted to clinical chemistry and laboratory medicine. EUROMEDLAB 2022 combined a large scientific program with educational workshops and symposia providing cutting edge science and breakthrough technologies. Alongside this, there was an industry exhibition showcasing the latest innovations in the field of clinical chemistry, diagnostics, clinical microbiology and laboratory informatics.
LumiraDx exhibited at EUROMEDLAB live for the first time to present its LumiraDx point of care instrument which offers a broad menu of lab-comparable results on a single, portable diagnostic platform. The LumiraDx Platform is an innovative, next generation point of care diagnostic system that combines a small, portable instrument, advanced low cost test strip and seamless secure digital connectivity to the Cloud and hospital IT systems. The LumiraDx Platform and tests are designed on the same principles as lab analyzer systems, to deliver accurate results compared to laboratory reference assays across a number of parameters, in a portable, easy-to-use point of care solution. Easy and intuitive to use, it requires only basic training and is designed to be affordable and accessible at the point of care. The platform is designed to go wherever the patient is, whether this is in a hospital, medical office, pharmacy, or in other non-traditional settings such as schools or airports.
The LumiraDx Platform menu includes point of care tests for COVID-19 Antibody, INR and D-Dimer - with high levels of accuracy comparable to central lab-based tests - all of which have achieved CE Mark and are commercially available in Europe. LumiraDx has also developed a high sensitivity antigen test for COVID-19 on the LumiraDx Platform. The LumiraDx COVID-19 antigen test has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) and achieved CE Mark. The LumiraDx Platform and COVID-19 antigen tests are also available in Japan and Brazil and has been rolled out in more than 60 countries globally.
Related Links:
LumiraDx
Latest EUROMEDLAB 2022 News
- Sebia Displays Automated, High Throughput Capillary Electrophoresis (CE) Instruments at EUROMEDLAB 2022
- Snibe Showcases Maglumi X3 Fully Automatic CLIA System at EUROMEDLAB 2022
- Thermo Fisher Presents Cascadion SM Clinical Analyzer and LC-MS IVD Medical Devices at EUROMEDLAB 2022
- Binding Site Exhibits Special Protein Analyzer Optilite at EUROMEDLAB 2022
- DIRUI Presents High-End Diagnostic Systems for Hospitals and High-Volume Labs at EUROMEDLAB 2022
- DIESSE Diagnostica Demonstrates Advanced Immunoassay and ESR Analyzers at EUROMEDLAB 2022
- Gentian Diagnostics Exhibits Assays for Wide Range of Clinical Chemistry Platforms at EUROMEDLAB
- Ortho Presents Broad Menu of High-Performing Assays at EUROMEDLAB 2022
- Technopath Highlights Laboratory Solutions to Enhance QC Efficiencies at EUROMEDLAB 2022
- Mindray Demonstrates Latest IVD Innovations at EUROMEDLAB 2022
- Beckman Coulter Presents Virtual Showcase of Laboratory Solutions at EUROMEDLAB 2022
- Horiba Showcases Latest Hematology and Hemostasis Solutions at EUROMEDLAB 2022
- Sysmex Europe Exhibits New Products and Innovative Concepts in Infection Diagnostics at EUROMEDLAB 2022
- Roche Showcases the Future of Diagnostic Solutions at EUROMEDLAB 2022
- Siemens Showcases Broad Portfolio of Integrated IVD Solutions at EUROMEDLAB Munich
- EUROMEDLAB 2022 Showcases Breakthrough Technologies and Cutting Edge Scientific Advances in Clinical Lab Diagnostics